Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP (346 views) (PDF public 10 views)
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Abstract, Conference, Randomized Controlled Trial,
Impact factor: 2.408, 5-year impact factor: 2.458
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84876730691&partnerID=40&md5=5e6a0a4c47796c0ddd3e099c73fbcd52
Keywords: 18f-Fluoride Pet Ct, Bone Scan, Early Bone Pain, Radionuclide Therapy, Sm-153 Edtmp, Bisphosphonic Acid Derivative, Contrast Medium, Etidronic Acid Tc 99m, Fluorine 18, Lexidronam Samarium Sm 153, Nonsteroid Antiinflammatory Agent, Zoledronic Acid, Diagnostic Agent, Organometallic Compound, Organophosphorus Compound, Samarium Ethylenediaminetetramethylenephosphonate, Article, Bone Metastasis, Bone Scintiscanning, Cancer Palliative Therapy, Cancer Radiotherapy, Clinical Article, Computer Assisted Emission Tomography, Controlled Study, Early Intervention, Human, Prostate Cancer, Randomized Controlled Trial, Visual Analog Scale, Bone Tumor, Multimodal Imaging, Pain Assessment, Pathology, Prostate Tumor, Bone Neoplasms, Fluorine Radioisotopes, Pain Measurement, Palliative Care, Prostatic Neoplasms, Time Factors, Bone Neoplasms Complications Secondary, Fluorides Diagnostic Use, Fluorine Radioisotopes Diagnostic Use, Organometallic Compounds Therapeutic Use, Organophosphorus Compounds Therapeutic Use, Pain Complications Radionuclide Imaging Radiotherapy, Prostatic Neoplasms Pathology,
Affiliations:
*** IBB - CNR ***
IRCCS, CROB, Rionero in Vulture, Italy
Institute of Biostructure and Bioimages, National Council of Research, Naples, Italy
Diagnostica per Immagini e Radioterapia, Università di Salerno, Salerno, Italy
References:
Resche, I., Chatal, J.F., Pecking, A., A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases (1997) Eur J Cancer, 33, pp. 1583-159
Sartor, O., Reid, R.H., Hoskin, P.J., Quadramet 424Sm10/11 Study Group. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer (2004) Urology, 63, pp. 940-945
Serafini, A.N., Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastasis (2000) Cancer, 88, pp. 2934-2939
Serafini, A.N., Houston, S.J., Resche, I., Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial (1998) J Clin Oncol, 16, pp. 1574-1581
Ricci, S., Boni, G., Pastina, I., Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer (2007) Eur J Nucl Med Mol Imaging, 34, pp. 1023-1030
Sciuto, R., Festa, A., Rea, S., Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial (2002) J Nucl Med, 43, pp. 79-86
Storto, G., Klain, M., Paone, G., Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (2006) Bone, 39, pp. 35-41
Thrall, J.H., Technetium-99m labeled agents for skeletal imaging (1976) CRC Crit Rev Clin Radiol Nucl Med, 8, pp. 1-31
Davis, M.A., Jones, A.G., Comparison of 99mTc-labeled phosphate and phosphonate agents for skeletal imaging (1976) Semin Nucl Med, 6, pp. 19-31
Hawkins, R.A., Choi, Y., Huang, S.C., Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET (1992) J Nucl Med, 33, pp. 633-642
Hoh, C.K., Hawkins, R.A., Dahlbom, M., Whole body skeletal imaging with [18F]fluoride ion and PET (1993) J Comput Assist Tomogr, 17, pp. 34-41
Schirrmeister, H., Guhlmann, A., Elsner, K., Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET (1999) J Nucl Med, 40, pp. 1623-1629
Tse, N., Hoh, C., Hawkins, R., Phelps, M., Glaspy, J., Positron emission tomography diagnosis of pulmonary metastases in osteogenic sarcoma (1994) Am J Clin Oncol, 17, pp. 22-25
Collins, C., Eary, J.F., Donaldson, G., Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial (1993) J Nucl Med, 34, pp. 1839-1844
Pandit-Taskar, N., Batraki, M., Divgi, C.R., Radiopharmaceutical therapy for palliation of bone pain from osseous metastases (2004) J Nucl Med, 45, pp. 1358-1365
Keller, E.T., Brown, J., Prostate cancer bone metastases promote both osteolytic and osteoblastic activity (2004) J Cell Biol, 91, pp. 718-729
Ribiero, M., Ruff, P., Falkson, G., Low serum testosterone and a younger age predict poor outcome in metastatic prostate cancer (1997) Am J Clin Oncol, 20, pp. 605-608
Auclerc, G., Antoine, E.C., Cajfinger, F., Brunet-Pommeyrol, A., Agazia, C., Khayat, D., Management of advanced prostate cancer (2000) Oncologist, 5, pp. 36-44
Reich, C.D., Advances in the treatment of bone metastases (2003) Clin J Oncol Nurs, 7, pp. 641-646
Coronado, M., Redondo, A., Coya, J., Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease (2006) Clin Nucl Med, 31, pp. 605-610
Serafini, A.N., Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis (2001) Q J Nucl Med, 45, pp. 91-99
Lewington, V.J., Bone-seeking radionuclides for therapy (2005) J Nucl Med, 46, pp. 38S-47S
Turner, J.H., Claringbold, P.G., A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate (1991) Eur J Cancer, 27, pp. 1085-1086
Porter, A.T., McEwan, A.J., Powe, J.E., Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer (1993) Int J Radiat Oncol Biol Phys, 25, pp. 805-813
Quilty, P.M., Kirk, D., Bolger, J.J., A comparison of the effects of strontium-89 and external beam radiotherapy in metastatic prostatic carcinoma (1994) Radiother Oncol, 31, pp. 33-40
Iagaru, A., Mittra, E., Yaghoubi, S.S., Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study (2009) J Nucl Med, 50, pp. 501-505
Hetzel, M., Arslandemir, C., König, H.H., F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management (2003) J Bone Miner Res, 18, pp. 2206-2214
Langsteger, W., Heinisch, M., Fogelman, I., The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast (2006) Semin Nucl Med, 36, pp. 73-92
Yen, R.F., Chen, C.Y., Cheng, M.F., The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients (2010) Nucl Med Commun, 31, pp. 637-645
Even-Sapir, E., Metser, U., Mishani, E., Lievshitz, G., Lerman, H., Leibovitch, I., The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18Ffluoride PET, and 18F-fluoride PET/CT (2006) J Nucl Med, 47, pp. 287-297
Petren-Mallmin, M., Andreasson, I., Ljunggren, O., Skeletal metastases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT (1998) Skeletal Radiol, 27, pp. 72-76
Grant, F.D., Fahey, F.H., Packard, A.B., Davis, R.T., Alavi, A., Treves, S.T., Skeletal PET with 18F-fluoride: applying new technology to an old tracer (2008) J Nucl Med, 49, pp. 68-78
Park-Holohan, S.J., Blake, G.M., Fogelman, I., Quantitative studies of bone using 18Ffluoride and 99mTc-methylene diphosphonate: evaluation of renal and whole blood kinetics (2001) Nucl Med Commun, 22, pp. 1037-1044
Kawaguchi, M., Tateishi, U., Shizukuishi, K., Suzuki, A., Inoue, T., 18F-fluoride uptake in bone metastasis: morphologic and metabolic analysis on integrated PET/CT (2010) Ann Nucl Med, 24, pp. 241-247
Beheshti, M., Vali, R., Waldenberger, P., Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study (2008) Eur J Nucl Med Mol Imaging, 35, pp. 1766-1774
Lewington, V.J., Cancer therapy using bone-seeking isotopes (1996) Phys Med Biol, 41, pp. 2027-2042
Nucl Med Biol (ISSN: 0969-8051, 0883-2897, 0969-8051linking), 2013 May; 40(4): 518-523.
Export to BibTeX Export to EndNote
Paper type: Journal Article, Abstract, Conference, Randomized Controlled Trial,
Impact factor: 2.408, 5-year impact factor: 2.458
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84876730691&partnerID=40&md5=5e6a0a4c47796c0ddd3e099c73fbcd52
Keywords: 18f-Fluoride Pet Ct, Bone Scan, Early Bone Pain, Radionuclide Therapy, Sm-153 Edtmp, Bisphosphonic Acid Derivative, Contrast Medium, Etidronic Acid Tc 99m, Fluorine 18, Lexidronam Samarium Sm 153, Nonsteroid Antiinflammatory Agent, Zoledronic Acid, Diagnostic Agent, Organometallic Compound, Organophosphorus Compound, Samarium Ethylenediaminetetramethylenephosphonate, Article, Bone Metastasis, Bone Scintiscanning, Cancer Palliative Therapy, Cancer Radiotherapy, Clinical Article, Computer Assisted Emission Tomography, Controlled Study, Early Intervention, Human, Prostate Cancer, Randomized Controlled Trial, Visual Analog Scale, Bone Tumor, Multimodal Imaging, Pain Assessment, Pathology, Prostate Tumor, Bone Neoplasms, Fluorine Radioisotopes, Pain Measurement, Palliative Care, Prostatic Neoplasms, Time Factors, Bone Neoplasms Complications Secondary, Fluorides Diagnostic Use, Fluorine Radioisotopes Diagnostic Use, Organometallic Compounds Therapeutic Use, Organophosphorus Compounds Therapeutic Use, Pain Complications Radionuclide Imaging Radiotherapy, Prostatic Neoplasms Pathology,
Affiliations:
*** IBB - CNR ***
IRCCS, CROB, Rionero in Vulture, Italy
Institute of Biostructure and Bioimages, National Council of Research, Naples, Italy
Diagnostica per Immagini e Radioterapia, Università di Salerno, Salerno, Italy
References:
Resche, I., Chatal, J.F., Pecking, A., A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases (1997) Eur J Cancer, 33, pp. 1583-159
Sartor, O., Reid, R.H., Hoskin, P.J., Quadramet 424Sm10/11 Study Group. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer (2004) Urology, 63, pp. 940-945
Serafini, A.N., Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastasis (2000) Cancer, 88, pp. 2934-2939
Serafini, A.N., Houston, S.J., Resche, I., Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial (1998) J Clin Oncol, 16, pp. 1574-1581
Ricci, S., Boni, G., Pastina, I., Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer (2007) Eur J Nucl Med Mol Imaging, 34, pp. 1023-1030
Sciuto, R., Festa, A., Rea, S., Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial (2002) J Nucl Med, 43, pp. 79-86
Storto, G., Klain, M., Paone, G., Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (2006) Bone, 39, pp. 35-41
Thrall, J.H., Technetium-99m labeled agents for skeletal imaging (1976) CRC Crit Rev Clin Radiol Nucl Med, 8, pp. 1-31
Davis, M.A., Jones, A.G., Comparison of 99mTc-labeled phosphate and phosphonate agents for skeletal imaging (1976) Semin Nucl Med, 6, pp. 19-31
Hawkins, R.A., Choi, Y., Huang, S.C., Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET (1992) J Nucl Med, 33, pp. 633-642
Hoh, C.K., Hawkins, R.A., Dahlbom, M., Whole body skeletal imaging with [18F]fluoride ion and PET (1993) J Comput Assist Tomogr, 17, pp. 34-41
Schirrmeister, H., Guhlmann, A., Elsner, K., Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET (1999) J Nucl Med, 40, pp. 1623-1629
Tse, N., Hoh, C., Hawkins, R., Phelps, M., Glaspy, J., Positron emission tomography diagnosis of pulmonary metastases in osteogenic sarcoma (1994) Am J Clin Oncol, 17, pp. 22-25
Collins, C., Eary, J.F., Donaldson, G., Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial (1993) J Nucl Med, 34, pp. 1839-1844
Pandit-Taskar, N., Batraki, M., Divgi, C.R., Radiopharmaceutical therapy for palliation of bone pain from osseous metastases (2004) J Nucl Med, 45, pp. 1358-1365
Keller, E.T., Brown, J., Prostate cancer bone metastases promote both osteolytic and osteoblastic activity (2004) J Cell Biol, 91, pp. 718-729
Ribiero, M., Ruff, P., Falkson, G., Low serum testosterone and a younger age predict poor outcome in metastatic prostate cancer (1997) Am J Clin Oncol, 20, pp. 605-608
Auclerc, G., Antoine, E.C., Cajfinger, F., Brunet-Pommeyrol, A., Agazia, C., Khayat, D., Management of advanced prostate cancer (2000) Oncologist, 5, pp. 36-44
Reich, C.D., Advances in the treatment of bone metastases (2003) Clin J Oncol Nurs, 7, pp. 641-646
Coronado, M., Redondo, A., Coya, J., Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease (2006) Clin Nucl Med, 31, pp. 605-610
Serafini, A.N., Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis (2001) Q J Nucl Med, 45, pp. 91-99
Lewington, V.J., Bone-seeking radionuclides for therapy (2005) J Nucl Med, 46, pp. 38S-47S
Turner, J.H., Claringbold, P.G., A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate (1991) Eur J Cancer, 27, pp. 1085-1086
Porter, A.T., McEwan, A.J., Powe, J.E., Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer (1993) Int J Radiat Oncol Biol Phys, 25, pp. 805-813
Quilty, P.M., Kirk, D., Bolger, J.J., A comparison of the effects of strontium-89 and external beam radiotherapy in metastatic prostatic carcinoma (1994) Radiother Oncol, 31, pp. 33-40
Iagaru, A., Mittra, E., Yaghoubi, S.S., Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study (2009) J Nucl Med, 50, pp. 501-505
Hetzel, M., Arslandemir, C., König, H.H., F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management (2003) J Bone Miner Res, 18, pp. 2206-2214
Langsteger, W., Heinisch, M., Fogelman, I., The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast (2006) Semin Nucl Med, 36, pp. 73-92
Yen, R.F., Chen, C.Y., Cheng, M.F., The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients (2010) Nucl Med Commun, 31, pp. 637-645
Even-Sapir, E., Metser, U., Mishani, E., Lievshitz, G., Lerman, H., Leibovitch, I., The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18Ffluoride PET, and 18F-fluoride PET/CT (2006) J Nucl Med, 47, pp. 287-297
Petren-Mallmin, M., Andreasson, I., Ljunggren, O., Skeletal metastases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT (1998) Skeletal Radiol, 27, pp. 72-76
Grant, F.D., Fahey, F.H., Packard, A.B., Davis, R.T., Alavi, A., Treves, S.T., Skeletal PET with 18F-fluoride: applying new technology to an old tracer (2008) J Nucl Med, 49, pp. 68-78
Park-Holohan, S.J., Blake, G.M., Fogelman, I., Quantitative studies of bone using 18Ffluoride and 99mTc-methylene diphosphonate: evaluation of renal and whole blood kinetics (2001) Nucl Med Commun, 22, pp. 1037-1044
Kawaguchi, M., Tateishi, U., Shizukuishi, K., Suzuki, A., Inoue, T., 18F-fluoride uptake in bone metastasis: morphologic and metabolic analysis on integrated PET/CT (2010) Ann Nucl Med, 24, pp. 241-247
Beheshti, M., Vali, R., Waldenberger, P., Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study (2008) Eur J Nucl Med Mol Imaging, 35, pp. 1766-1774
Lewington, V.J., Cancer therapy using bone-seeking isotopes (1996) Phys Med Biol, 41, pp. 2027-2042
Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP
This study evaluated the diagnostic impact of using skeletal F-18-fluoride PET/CT on patients with painful bone metastases to schedule an early palliative radionuclide treatment. Methods: The skeletal involvement from prostate cancer metastases was assessed by both Tc-99m-diphosphonate bone scan (BS) and F-18-fluoride PET/CT within four weeks in 24 patients (67.7 +/- 5.1 years) suffering from a borderline degree of bone pain for which radionuclide palliation was not shortly planned for administration. The BS and F-18-fluoride PET/CT results were compared, assessing the number and extension of the skeletal sites involved. Afterward, the patients were randomly assigned either to the study group (N = 12) receiving radionuclide therapy (Samarium-153 EDTMP) or to the control group (N = 12) not receiving radionuclide therapy. The short-term results from the radionuclide palliation group (evaluated with a visual analogue scale) were compared with the controls. Results: Overall, at BS, 7.6 +/- 1.4 sites were considered metastatic, involving at least 5 +/- 1 body regions. At F-18-fluoride PET/CT, 116 +/- 19 sites presented metastatic involvement with 12/12 body regions concerned. No differences were found in regards to either the number of metastatic sites or regions at both BS and F-18-fluoride PET/CT between the study group and controls (p = ns). At CT, 88 blastic metastases were identified, whereas 110 were mainly lytic. Most of mainly lytic lesions were not detectable at BS. The reduction in total discomfort and bone pain in the study group was significantly greater than in the controls (p < 0.0001). Conclusion: Sm-153 EDTMP therapy should be considered for patients with early bone pain from prostate cancer even if their BS only indicates a few metastases before the initiation of a severe pain syndrome. F-18-fluoride PET/CT may be helpful in deciding if the implementation of bone pain palliation using bone-seeking radionuclides at pain onset is necessary. (C) 2013 Elsevier Inc. All rights reserved.
This study evaluated the diagnostic impact of using skeletal F-18-fluoride PET/CT on patients with painful bone metastases to schedule an early palliative radionuclide treatment. Methods: The skeletal involvement from prostate cancer metastases was assessed by both Tc-99m-diphosphonate bone scan (BS) and F-18-fluoride PET/CT within four weeks in 24 patients (67.7 +/- 5.1 years) suffering from a borderline degree of bone pain for which radionuclide palliation was not shortly planned for administration. The BS and F-18-fluoride PET/CT results were compared, assessing the number and extension of the skeletal sites involved. Afterward, the patients were randomly assigned either to the study group (N = 12) receiving radionuclide therapy (Samarium-153 EDTMP) or to the control group (N = 12) not receiving radionuclide therapy. The short-term results from the radionuclide palliation group (evaluated with a visual analogue scale) were compared with the controls. Results: Overall, at BS, 7.6 +/- 1.4 sites were considered metastatic, involving at least 5 +/- 1 body regions. At F-18-fluoride PET/CT, 116 +/- 19 sites presented metastatic involvement with 12/12 body regions concerned. No differences were found in regards to either the number of metastatic sites or regions at both BS and F-18-fluoride PET/CT between the study group and controls (p = ns). At CT, 88 blastic metastases were identified, whereas 110 were mainly lytic. Most of mainly lytic lesions were not detectable at BS. The reduction in total discomfort and bone pain in the study group was significantly greater than in the controls (p < 0.0001). Conclusion: Sm-153 EDTMP therapy should be considered for patients with early bone pain from prostate cancer even if their BS only indicates a few metastases before the initiation of a severe pain syndrome. F-18-fluoride PET/CT may be helpful in deciding if the implementation of bone pain palliation using bone-seeking radionuclides at pain onset is necessary. (C) 2013 Elsevier Inc. All rights reserved.
Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP
No results. |
Impact of F-18-fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP
Other filter: ([btitle,keywords] "18f-Fluoride Pet Ct" ...
Gallicchio R, Scapicchio D, Nardelli A, Pellegrino T, Prisco M, Mainenti P, Sirignano C, Pedicini P, Storto G
* Assessment of residual radioactivity by a comprehensive wireless, wearable device in thyroid cancer patients undergoing radionuclide therapy and comparison with the results of a home device: a feasibility study (46 views) (PDF 17 views)
Ieee J Transl Eng Health Med (ISSN: 2168-2372linking), 2020 Dec 2; 9: 2700306-2700306.
Impact Factor: 2.53
View Export to BibTeX Export to EndNote
Gallicchio R, Giacomobono S, Nardelli A, Pellegrino T, Simeon V, Gattozzi D, Maddalena F, Mainenti PP, Storto G
* Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain (395 views)
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Impact Factor: 2.46
View Export to BibTeX Export to EndNote
D'Antuono F, Nardelli A, Gallicchio R, Giacomobono S, Venetucci A, Pellegrino T, Leggiadro F, D'Errico N, Gattozzi D, Mainenti PP, Storto G
* Palliative Treatment of Bone Metastases with Sm-153 EDTMP at Pain Onset (287 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pace L, Salvatore M
* Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90 (453 views)
Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2011 Jan; 69(1): 52-55.
Impact Factor: 1.172
View Export to BibTeX Export to EndNote
Fabbricini R, Catalano L, Pace L, Del Vecchio S, Fonti R, Salvatore M, Rotoli B
* Bone scintigraphy and SPECT/CT in bisphosphonate-induced osteonecrosis of the jaw (287 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2009 Aug; 50(8): 1385-1385.
Impact Factor: 6.424
View Export to BibTeX Export to EndNote
Storto G, Erra P, Pellegrino T, Nardelli A, Milone F, Di Giorgio E, Faggiano A, Castaldi E, Ortosecco G, Speranza A, Klain M, Colao A, Salvatore M, Pace L
* Efficacy and Toxicity of Peptide Receptor Radionuclide Therapy (PRRT) using medium-high activities of Y-90-DOTA-Octreotate (Y-90-DOTATATE) in patients with tumours expressing somatostatin receptors (SSTR) (260 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Storto G, Pellegrino T, Nardelli A, De Falco T, Castaldi E, Ortosecco G, Capasso E, Erra P, Speranza A, Klain M, Molino L, Di Nuzzo C, Pace L, Salvatore M
* Impact of PET-CT with F-18 Fluoride in Implementing Treatment of Painful Bone Metastases with Sm-153 EDTMP (288 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Catalano L, Del Vecchio S, Petruzziello F, Fonti R, Salvatore B, Martorelli C, Califano C, Caparrotti G, Segreto S, Pace L, Rotoli B
* Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis (412 views)
Ann Hematol (ISSN: 0939-5555, 0939-5555linking), 2007 Jun; 86(6): 415-423.
Impact Factor: 2.342
View Export to BibTeX Export to EndNote
Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M
* Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (390 views)
Bone (ISSN: 8756-3282), 2006 Jul; 39(1): 35-41.
Impact Factor: 3.829
View Export to BibTeX Export to EndNote
Storto G, Speranza A, Pellegrino T, Panico M, Cella L, Nardelli A, Russo AA, Klain M, Soricelli A, Pace L, Salvatore M
* Activity Threshold Determining Cumulative Aderse-Effects In Patients Undergoing Peptide Receptor Radionuclide Therapy With Y-90 Octreotate (290 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006; 33: 338-338.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Rendina D, Mossetti G, Soscia E, Sirignano C, Insabato L, Viceconti R, Ignarra R, Salvatore M, Nunziata V
* Giant cell tumor and Paget's disease of bone in one family: geographic clustering (353 views)
Clinical Orthopaedics And Related Research (ISSN: 0009-921x), 2004 Apr; (421): 218-224.
Impact Factor: 1.403
View Export to BibTeX Export to EndNote
* Assessment of residual radioactivity by a comprehensive wireless, wearable device in thyroid cancer patients undergoing radionuclide therapy and comparison with the results of a home device: a feasibility study (46 views) (PDF 17 views)
Ieee J Transl Eng Health Med (ISSN: 2168-2372linking), 2020 Dec 2; 9: 2700306-2700306.
Impact Factor: 2.53
View Export to BibTeX Export to EndNote
Gallicchio R, Giacomobono S, Nardelli A, Pellegrino T, Simeon V, Gattozzi D, Maddalena F, Mainenti PP, Storto G
* Palliative Treatment Of Bone Metastases With Samarium-153 Edtmp At Onset Of Pain (395 views)
J Bone Miner Metab (ISSN: 0914-8779), 2014 Jul; 32(4): 434-440.
Impact Factor: 2.46
View Export to BibTeX Export to EndNote
D'Antuono F, Nardelli A, Gallicchio R, Giacomobono S, Venetucci A, Pellegrino T, Leggiadro F, D'Errico N, Gattozzi D, Mainenti PP, Storto G
* Palliative Treatment of Bone Metastases with Sm-153 EDTMP at Pain Onset (287 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2013 Oct; 40: N/D-N/D.
Impact Factor: 5.217
View Export to BibTeX Export to EndNote
Nardelli A, Castaldi E, Ortosecco G, Speranza A, Storto G, Pace L, Salvatore M
* Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90 (453 views)
Applied Radiation And Isotopes (ISSN: 1872-9800, 0969-8043, 0969-8043linking), 2011 Jan; 69(1): 52-55.
Impact Factor: 1.172
View Export to BibTeX Export to EndNote
Fabbricini R, Catalano L, Pace L, Del Vecchio S, Fonti R, Salvatore M, Rotoli B
* Bone scintigraphy and SPECT/CT in bisphosphonate-induced osteonecrosis of the jaw (287 views)
J Nucl Med (ISSN: 0161-5505, 1535-5667, 1535-5667electronic), 2009 Aug; 50(8): 1385-1385.
Impact Factor: 6.424
View Export to BibTeX Export to EndNote
Storto G, Erra P, Pellegrino T, Nardelli A, Milone F, Di Giorgio E, Faggiano A, Castaldi E, Ortosecco G, Speranza A, Klain M, Colao A, Salvatore M, Pace L
* Efficacy and Toxicity of Peptide Receptor Radionuclide Therapy (PRRT) using medium-high activities of Y-90-DOTA-Octreotate (Y-90-DOTATATE) in patients with tumours expressing somatostatin receptors (SSTR) (260 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Storto G, Pellegrino T, Nardelli A, De Falco T, Castaldi E, Ortosecco G, Capasso E, Erra P, Speranza A, Klain M, Molino L, Di Nuzzo C, Pace L, Salvatore M
* Impact of PET-CT with F-18 Fluoride in Implementing Treatment of Painful Bone Metastases with Sm-153 EDTMP (288 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2008 Oct; 35: N/D-N/D.
Impact Factor: 4.532
View Export to BibTeX Export to EndNote
Catalano L, Del Vecchio S, Petruzziello F, Fonti R, Salvatore B, Martorelli C, Califano C, Caparrotti G, Segreto S, Pace L, Rotoli B
* Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis (412 views)
Ann Hematol (ISSN: 0939-5555, 0939-5555linking), 2007 Jun; 86(6): 415-423.
Impact Factor: 2.342
View Export to BibTeX Export to EndNote
Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M
* Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases (390 views)
Bone (ISSN: 8756-3282), 2006 Jul; 39(1): 35-41.
Impact Factor: 3.829
View Export to BibTeX Export to EndNote
Storto G, Speranza A, Pellegrino T, Panico M, Cella L, Nardelli A, Russo AA, Klain M, Soricelli A, Pace L, Salvatore M
* Activity Threshold Determining Cumulative Aderse-Effects In Patients Undergoing Peptide Receptor Radionuclide Therapy With Y-90 Octreotate (290 views)
Eur J Nucl Med (ISSN: 1619-7070, 1619-7089, 0340-6997), 2006; 33: 338-338.
Impact Factor: 4.041
View Export to BibTeX Export to EndNote
Rendina D, Mossetti G, Soscia E, Sirignano C, Insabato L, Viceconti R, Ignarra R, Salvatore M, Nunziata V
* Giant cell tumor and Paget's disease of bone in one family: geographic clustering (353 views)
Clinical Orthopaedics And Related Research (ISSN: 0009-921x), 2004 Apr; (421): 218-224.
Impact Factor: 1.403
View Export to BibTeX Export to EndNote
11 Records (7 excluding Abstracts).
Total impact factor: 38.482 (20.16 excluding Abstracts).
Total 5 year impact factor: 37.759 (19.053 excluding Abstracts).
Total impact factor: 38.482 (20.16 excluding Abstracts).
Total 5 year impact factor: 37.759 (19.053 excluding Abstracts).
346 views. Last view on Saturday 14 January 2023, 17:57:34
ibb.cnr.it
